Table 1.

Study Participants

Characteristics	Total (N = 127)
Age at ART initiation, y, median (IQR)	32 (27–44)
Male sex, No. (%)	117 (92.1)
Pre-ART CD4 T-cell count, cells/μL, median (IQR)	348 (258–459)
Pre-ART CD4/CD8 ratio, median (IQR)	0.36 (0.25–0.49)
Pre-ART HIV RNAa, log10 copies/mL, median (IQR)	4.61 (4.15–5.05)
ART regimen, No. (%)
TDF + 3TC + EFV	116 (91.3)
ZDV + 3TC + EFV/NVP	7 (5.5)
TDF + 3TC + RAL	2 (1.6)
TDF + 3TC + LPV/r	2 (1.6)
ART duration, mo, median (IQR)	15 (12–27)
On-ART CD4 T-cell count, cells/μL, median (IQR)	403 (332–560)
On-ART CD4/CD8 ratio, median (IQR)	0.62 (0.45–0.87)

Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy, EFV, efavirenz; HIV, human immunodeficiency virus; IQR, interquartile range; LPV/r, lopinavir/ritonavir; NVP, nevirapine; RAL, raltegravir; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.

^aData from 99 participants.